Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer (Q44331655)

2 December 2017

title

Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer (English)

1 reference

2 December 2017

1 reference

2 December 2017

Hua-Jun Chen

1 reference

2 December 2017

Hong-Hong Yan

1 reference

2 December 2017

Jin-Ji Yang

1 reference

2 December 2017

Zhi-Hong Chen

1 reference

2 December 2017

Jian Su

1 reference

2 December 2017

Xu-Chao Zhang

1 reference

2 December 2017

publication date

29 May 2013

1 reference

Pathology and Oncology Research

2 December 2017

published in

1 reference

2 December 2017

1 reference

2 December 2017

1 reference

2 December 2017

page(s)

833-838

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Non–Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

The 2004 World Health Organization classification of lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

The new lung cancer staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Pronostic factors of synchronous brain metastases from lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12253-013-9651-Z

10.1007/S12253-013-9651-Z

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference